MaxCyte, Inc. (MXCT) stock

MXCTNasdaqServices-Commercial Physical & Biological ResearchFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 11/3065% below fair value

$1.10−0.03 (-2.65%)

Close on Nov 11, 2026Market cap $113.53MP/E –Yield –

MaxCyte gross margin

Gross margin is gross profit as a percentage of revenue.

MaxCyte's gross margin for the twelve months ending Sep 30, 2026 was 81.0%. For fiscal 2025 it was 81.2%, against 81.6% the year before. The highest annual figure on record is 89.4% in fiscal 2020.

Annual gross margin

Period	Period end	Value	Change (pts)
FY2025	Dec 31, 2025	81.2%	−0.5
FY2024	Dec 31, 2024	81.6%	−6.9
FY2023	Dec 31, 2023	88.5%	+0.0
FY2022	Dec 31, 2022	88.5%	−0.8
FY2021	Dec 31, 2021	89.2%	−0.2
FY2020	Dec 31, 2020	89.4%	+1.0
FY2019	Dec 31, 2019	88.4%	–

Quarterly gross margin

Change is against the same quarter a year earlier.

Period	Period end	Value	Change (pts)
Q3 FY2026	Sep 30, 2026	83.4%	+6.8
Q2 FY2026	Jun 30, 2026	77.0%	−5.2
Q1 FY2026	Mar 31, 2026	83.7%	−1.8
Q4 FY2025	Dec 31, 2025	77.9%	+4.2
Q3 FY2025	Sep 30, 2025	76.6%	+0.2
Q2 FY2025	Jun 30, 2025	82.1%	−3.6
Q1 FY2025	Mar 31, 2025	85.6%	−2.0
Q4 FY2024	Dec 31, 2024	73.8%	−16.2
Q3 FY2024	Sep 30, 2024	76.4%	−13.7
Q2 FY2024	Jun 30, 2024	85.7%	+0.9
Q1 FY2024	Mar 31, 2024	87.6%	−0.7
Q4 FY2023	Dec 31, 2023	90.0%	+2.4
Q3 FY2023	Sep 30, 2023	90.1%	+3.0
Q2 FY2023	Jun 30, 2023	84.8%	−3.6
Q1 FY2023	Mar 31, 2023	88.3%	−2.5
Q4 FY2022	Dec 31, 2022	87.6%	−0.4
Q3 FY2022	Sep 30, 2022	87.1%	−3.6
Q2 FY2022	Jun 30, 2022	88.3%	−0.6
Q1 FY2022	Mar 31, 2022	90.8%	+1.5
Q4 FY2021	Dec 31, 2021	87.9%	−1.4
Q3 FY2021	Sep 30, 2021	90.7%	+1.6
Q2 FY2021	Jun 30, 2021	89.0%	−2.0
Q1 FY2021	Mar 31, 2021	89.3%	–
Q4 FY2020	Dec 31, 2020	89.3%	–
Q3 FY2020	Sep 30, 2020	89.1%	–
Q2 FY2020	Jun 30, 2020	90.9%	–